News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Upstream Biosciences Inc. Announces Agreement With GENpathway Inc. to Advance Biomarker Validation Studies


7/10/2007 1:13:43 PM

VANCOUVER, BC--(MARKET WIRE)--Jul 10, 2007 -- Upstream Biosciences Inc. (OTC BB:UPBS.OB - News), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, today announced that it has retained Genpathway, Inc. to conduct analysis using its highly sensitive chromatin immunoprecipitation assays. The analysis is intended to provide critical information for the next phase of Upstream's program to validate its first two cancer biomarkers and drug response assay. Genpathway will apply its assays to help elucidate critical parameters involving specific gene transcription factors and pathways.

Read at Market Wired


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES